Insight Molecular Diagnostics (IMDX) Accounts Payables (2015 - 2026)

Insight Molecular Diagnostics (IMDX) has 12 years of Accounts Payables data on file, last reported at $1.6 million in Q1 2026.

• Quarterly Accounts Payables fell 29.14% year-over-year to $1.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.6 million (down 29.14% YoY) and the FY2025 annual result came in at $2.5 million, up 508.61% from the prior year.
• Accounts Payables declined to $1.6 million in Q1 2026 per IMDX's latest filing, from $2.5 million in the prior quarter.
• The five-year high for Accounts Payables was $4.6 million in Q2 2022, with the low at $379000.0 in Q2 2024.
• Average Accounts Payables over 5 years is $1.7 million, with a median of $1.3 million recorded in 2022.
• Year-over-year, Accounts Payables tumbled 82.74% in 2024 and soared 508.61% in 2025.
• Insight Molecular Diagnostics' Accounts Payables stood at $1.3 million in 2022, then declined by 23.94% to $953000.0 in 2023, then plunged by 56.14% to $418000.0 in 2024, then soared by 508.61% to $2.5 million in 2025, then slumped by 36.52% to $1.6 million in 2026.
• Business Quant data shows IMDX's Accounts Payables at $1.6 million in Q1 2026, $2.5 million in Q4 2025, and $602000.0 in Q3 2025.